Radiation enteritis.
The frequent use of radiotherapy for abdominal and pelvic malignancies results in an increased risk of radiation enteritis. An increased understanding of the tissue response and the clinical features of radiation enteritis has led to advances in the prevention and management of this condition. Importantly, improvements in the delivery of radiotherapy, including techniques to reduce the amount of exposed small intestine in the radiation field, represent a critical strategy for prevention. Data indicate that radioprotectant agents have the potential to reduce intestinal mucosal injury and may be beneficial in reducing both acute and chronic side effects of radiotherapy.
Bismar
Mike M
MM
Department of Gastrointestinal Medicine and Nutrition, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 436, Houston, TX 77030, USA.
Sinicrope
Frank A
FA
D000008:Abdominal Neoplasms / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D004382:Duodenitis / Q000453:epidemiology / Q000209:etiology; D004751:Enteritis / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D006801:Humans; D007079:Ileitis / Q000453:epidemiology / Q000209:etiology; D015994:Incidence; D007413:Intestinal Mucosa / Q000528:radiation effects; D007579:Jejunal Diseases / Q000453:epidemiology / Q000209:etiology; D008297:Male; D010386:Pelvic Neoplasms / Q000532:radiotherapy*; D011379:Prognosis; D011832:Radiation Injuries / Q000453:epidemiology* / Q000517:prevention & control; D011837:Radiation-Protective Agents / Q000008:administration & dosage; D011878:Radiotherapy / Q000009:adverse effects*; D011879:Radiotherapy Dosage; D018570:Risk Assessment
D011837:Radiation-Protective Agents